{
  "id": "279b7c7293a8b819",
  "title": "Recce advances Phase 3 DFI trial and reports new pneumonia data in December quarter",
  "description": "Recce Pharmaceuticals Ltd has reported solid operational momentum in its December 2025 quarter, highlighted by continued progress in its registrational...",
  "content": "![logo-loader](https://cdn.proactiveinvestors.com/assets/svg/loader-logo-rotate.svg)\n\n![](https://cdn.proactiveinvestors.com/assets/img/logo.png)\n\n[Health](https://www.proactiveinvestors.com/health) [Pharma & Biotech](https://www.proactiveinvestors.com/pharma)\n\nWritten by:\n\n[**Lisa Uhlman**](https://www.proactiveinvestors.com/teams/details/464/Lisa-Uhlman)\n\nThis record is published on behalf of Recce Pharmaceuticals Ltd, a paid client of Proactive\n\n[About this content](https://www.proactiveinvestors.com/companies/news/1086539/recce-advances-phase-3-dfi-trial-and-reports-new-pneumonia-data-in-december-quarter-1086539.html#) [Disclaimer\\\\\n\\\\\nNo investment advice](https://www.proactiveinvestors.com/companies/news/1086539/recce-advances-phase-3-dfi-trial-and-reports-new-pneumonia-data-in-december-quarter-1086539.html#)\n\nShare article\n\n[Recce Pharmaceuticals Ltd](https://www.proactiveinvestors.com/ASX:RCE/Recce-Pharmaceuticals-Ltd/)\n\n(\n\nASX:RCEOTC:RECEF\n\n)\n\n[View Price & Profile](https://www.proactiveinvestors.com/ASX:RCE/Recce-Pharmaceuticals-Ltd/)\n\n# Recce advances Phase 3 DFI trial and reports new pneumonia data in December quarter\n\nPublished: 22:43 29 Jan 2026 EST\n\n\n![Recce Pharmaceuticals Ltd - Recce advances Phase 3 DFI trial and reports new pneumonia data in December quarter](https://cdn.proactiveinvestors.com/eyJidWNrZXQiOiJwYS1jZG4iLCJrZXkiOiJ1cGxvYWRcL05ld3NcL0ltYWdlXC8yMDI2XzAxXC8yMDIxLTEyLTA3LTEyLTE1LTE5LTIzZjhlYTc0NjMwMWQ4ZDQ1NzAzNWM4MDU3ZTM1YTQzLmpwZyIsImVkaXRzIjp7InJlc2l6ZSI6eyJ3aWR0aCI6MTI4MCwiaGVpZ2h0Ijo3MjAsImZpdCI6ImNvdmVyIn19fQ==)\n\nRecce Pharmaceuticals Ltd has reported solid operational momentum in its December 2025 quarter, highlighted by continued progress in its registrational Phase 3 clinical trial for diabetic foot infections (DFI) in Indonesia and encouraging new preclinical data for inhaled RECCE\u00ae 327 in hospital-acquired pneumonia models.\n\nThe company also strengthened its intellectual property position with a new Hong Kong patent grant and s",
  "source": "proactiveinvestors.com",
  "source_url": "https://www.proactiveinvestors.com/companies/news/1086539/recce-advances-phase-3-dfi-trial-and-reports-new-pneumonia-data-in-december-quarter-1086539.html",
  "published_at": "20260130T050000Z",
  "fetched_at": "2026-01-31T00:26:46.418942+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "United States",
  "raw_data": {
    "url": "https://www.proactiveinvestors.com/companies/news/1086539/recce-advances-phase-3-dfi-trial-and-reports-new-pneumonia-data-in-december-quarter-1086539.html",
    "url_mobile": "",
    "title": "Recce advances Phase 3 DFI trial and reports new pneumonia data in December quarter",
    "seendate": "20260130T050000Z",
    "socialimage": "https://cdn.proactiveinvestors.com/eyJidWNrZXQiOiJwYS1jZG4iLCJrZXkiOiJ1cGxvYWRcL05ld3NcL0ltYWdlXC8yMDI2XzAxXC8yMDIxLTEyLTA3LTEyLTE1LTE5LTIzZjhlYTc0NjMwMWQ4ZDQ1NzAzNWM4MDU3ZTM1YTQzLmpwZyIsImVkaXRzIjp7InJlc2l6ZSI6eyJ3aWR0aCI6MTIwMCwiaGVpZ2h0Ijo2MzAsImZpdCI6ImNvdmVyIn19fQ==",
    "domain": "proactiveinvestors.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}